TREM2介导MHCII相关的CD4+ T细胞抗胶质瘤免疫应答
研究分析胶质母细胞瘤患者样本及GL261小鼠胶质瘤模型,发现TREM2在肿瘤相关髓系细胞高表达;临床前模型中TREM2缺陷未带来获益,反而加速胶质瘤进展,机制涉及吞噬能力受损、MHCII表达降低及肿瘤半球内CD4+ T细胞减少。
要点
- 患者脑肿瘤TREM2表达显著高于其他类型肿瘤,主要定位于肿瘤相关髓系细胞。
- 临床前胶质瘤模型中TREM2缺陷加速肿瘤进展,未显示获益。
- TREM2缺陷损害肿瘤髓系细胞吞噬肿瘤细胞能力并降低MHCII表达。
核心结论
- 研究揭示肿瘤髓系细胞TREM2此前未被认识的保护作用,TREM2增强对肿瘤细胞的吞噬并促进MHCII相关CD4+ T细胞抗胶质瘤免疫应答。
研究设计与样本
- 研究分析多种患者肿瘤样本的TREM2表达谱,并对胶质母细胞瘤患者及GL261小鼠胶质瘤模型进行单细胞转录组分析。
- 研究使用多种小鼠胶质瘤模型,采用体内双光子成像、光谱流式细胞术及体外共培养实验评估TREM2功能。
主要发现
- 患者脑肿瘤中TREM2表达水平显著高于其他类型肿瘤。
- TREM2主要定位于肿瘤相关髓系细胞,在几乎所有微胶质细胞及多种巨噬细胞亚型中高表达。
- 临床前胶质瘤模型中TREM2缺陷未带来获益,反而加速胶质瘤进展。
- TREM2缺陷损害肿瘤髓系细胞吞噬肿瘤细胞的能力并导致MHCII表达降低。
- TREM2缺陷进一步显著减少肿瘤半球内CD4+ T细胞的存在。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. METHODS: We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres. RESULTS: Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres. CONCLUSIONS: Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.
引用
- Zheng J, Wang L, Zhao S, et al. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro Oncol. 2024. PMID: 37941134. doi:10.1093/neuonc/noad214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。